24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
NCT00976937 on ClinicalTrials.gov · last registry update 2016-10-11
Finished March 2011, after enrolling 319 people. lixisenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.
- Status
- COMPLETED
- Phase
- P3
- Drug
- lixisenatideSoliqua, Adlyxin
- Sponsor
- Sanofi
- Sponsor type
- Industry
- Enrollment
- 319
- Started
- 2009-08
- Primary completion
- 2011-03 actual
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-08-21 | First seen in registry | Registered as COMPLETED, P3 |
Primary outcome
Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% and at Least 5% Weight Loss From Baseline at Week 24
Conditions studied
Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.